tallózása szerző szerint "Lánczky A"

1-8 / 8

An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients

Győrffy, Balázs; Lánczky A; Eklund AC; Denkert C; Budczies J; Li Q; Szállási Z (2010)

Validating prognostic or predictive candidate genes in appropriately powered breast cancer cohorts are of utmost interest. Our aim was to develop an online tool to draw survival plots, which can be used to assess the ...
Cross-validation of survival associated biomarkers in gastric cancer using transcriptomic data of 1,065 patients

Szász, A Marcell; Lánczky A; Nagy, Ádám; Förster S; Hark K; Green JE; Boussioutas A; Busuttil R; Szabó, András; Győrffy, Balázs (2016)

INTRODUCTION: Multiple gene expression based prognostic biomarkers have been repeatedly identified in gastric carcinoma. However, without confirmation in an independent validation study, their clinical utility is limited. ...
Genome-wide reprogramming of the chromatin landscape underlies endocrine therapy resistance in breast cancer

Magnani L; Stoeck A; Zhang X; Lánczky A; Mirabella AC; Győrffy Balázs (2013)

The estrogen receptor (ER)α drives growth in two-thirds of all breast cancers. Several targeted therapies, collectively termed endocrine therapy, impingeonestrogen-induced ERα activationtoblock tumor growth. However, half ...
Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data of 1287 patients

Győrffy, Balázs; Lánczky A; Szállási Z (2012)
MEK1 is associated with carboplatin resistance and is a prognostic biomarker in epithelial ovarian cancer

Pénzváltó, Zsófia; Lánczky A; Lénárt J; Meggyesházi, Nóra; Krenács, Tibor; Szoboszlai, Norbert; Denkert C; Pete, Imre; Győrffy, Balázs (2014)

BACKGROUND: Primary systemic treatment for ovarian cancer is surgery, followed by platinum based chemotherapy. Platinum resistant cancers progress/recur in approximately 25% of cases within six months. We aimed to identify ...
miRpower: a web-tool to validate survival-associated miRNAs utilizing expression data from 2178 breast cancer patients

Lánczky A; Nagy, Ádám; Bottai G; Munkácsy, Gyöngyi; Szabó, András; Santarpia L; Győrffy, Balázs (2016)

PURPOSE: The proper validation of prognostic biomarkers is an important clinical issue in breast cancer research. MicroRNAs (miRNAs) have emerged as a new class of promising breast cancer biomarkers. In the present work, ...
Online Survival Analysis Software to Assess the Prognostic Value of Biomarkers Using Transcriptomic Data in Non-Small-Cell Lung Cancer

Győrffy Balázs; Surowiak P; Budczies J; Lánczky A (2013)
Systematic analysis of AU-rich element expression in cancer reveals common functional clusters regulated by key RNA-binding proteins

Hitti E; Bakheet T; Al-Souhibani N; Moghrabi W; Al-Yahya S; Al-Ghamdi M; Al-Saif M; Shoukri MM; Lánczky A; Grepin R; Győrffy, Balázs; Pagès G; Khabar KS (2016)

1-8 / 8

Keresés

Összetett keresés

Tallózás

Teljes repozitórumban

Hozzáférésem

Bejelentkezés

tallózása szerző szerint "Lánczky A"

DSpace/Manakin Repository

tallózása szerző szerint "Lánczky A"

Keresés

Tallózás

Teljes repozitórumban

Hozzáférésem